O	0	10	Expression	Expression	NN	B-NP
O	11	20	profiling	profiling	NN	I-NP
O	21	23	in	in	IN	B-PP
O	24	35	progressive	progressive	JJ	B-NP
O	36	42	stages	stage	NNS	I-NP
O	43	45	of	of	IN	B-PP
O	46	54	fumarate	fumarate	JJ	B-NP
O	54	55	-	-	HYPH	I-NP
O	55	64	hydratase	hydratase	NN	I-NP
O	65	75	deficiency	deficiency	NN	I-NP
O	75	76	:	:	:	O
O	77	80	the	the	DT	B-NP
O	81	93	contribution	contribution	NN	I-NP
O	94	96	of	of	IN	B-PP
O	97	106	metabolic	metabolic	JJ	B-NP
O	107	114	changes	change	NNS	I-NP
O	115	117	to	to	TO	B-PP
O	118	131	tumorigenesis	tumorigenesis	NN	B-NP
O	131	132	.	.	.	O

B-Cancer	133	143	Hereditary	Hereditary	JJ	B-NP
I-Cancer	144	158	leiomyomatosis	leiomyomatosis	NN	I-NP
I-Cancer	159	162	and	and	CC	O
I-Cancer	163	168	renal	renal	JJ	B-NP
I-Cancer	169	173	cell	cell	NN	I-NP
I-Cancer	174	183	carcinoma	carcinoma	NN	I-NP
O	184	185	(	(	(	O
B-Cancer	185	190	HLRCC	HLRCC	NN	B-NP
O	190	191	)	)	)	O
O	192	194	is	be	VBZ	B-VP
O	195	201	caused	cause	VBN	I-VP
O	202	204	by	by	IN	B-PP
O	205	214	mutations	mutation	NNS	B-NP
O	215	217	in	in	IN	B-PP
O	218	221	the	the	DT	B-NP
O	222	227	Krebs	Krebs	NNP	I-NP
O	228	233	cycle	cycle	NN	I-NP
O	234	240	enzyme	enzyme	NN	I-NP
O	241	249	fumarate	fumarate	JJ	I-NP
O	250	259	hydratase	hydratase	NN	I-NP
O	260	261	(	(	(	O
O	261	263	FH	FH	NN	B-NP
O	263	264	)	)	)	O
O	264	265	.	.	.	O

O	266	268	It	It	PRP	B-NP
O	269	272	has	have	VBZ	B-VP
O	273	277	been	be	VBN	I-VP
O	278	286	proposed	propose	VBN	I-VP
O	287	291	that	that	IN	B-SBAR
O	292	293	"	"	``	B-NP
O	293	306	pseudohypoxic	pseudohypoxic	JJ	I-NP
O	306	307	"	"	''	I-NP
O	308	321	stabilization	stabilization	NN	I-NP
O	322	324	of	of	IN	B-PP
O	325	332	hypoxia	hypoxia	NN	B-NP
O	332	333	-	-	HYPH	B-NP
O	333	342	inducible	inducible	JJ	I-NP
O	343	349	factor	factor	NN	I-NP
O	349	350	-	-	HYPH	O
O	350	355	alpha	alpha	SYM	B-NP
O	356	357	(	(	(	O
O	357	360	HIF	HIF	NN	B-NP
O	360	361	-	-	HYPH	B-NP
O	361	366	alpha	alpha	NN	I-NP
O	366	367	)	)	)	O
O	368	370	by	by	IN	B-PP
O	371	379	fumarate	fumarate	JJ	B-NP
O	380	392	accumulation	accumulation	NN	I-NP
O	393	404	contributes	contribute	VBZ	B-VP
O	405	407	to	to	TO	B-PP
O	408	421	tumorigenesis	tumorigenesis	NN	B-NP
O	422	424	in	in	IN	B-PP
B-Cancer	425	430	HLRCC	HLRCC	NN	B-NP
O	430	431	.	.	.	O

O	432	434	We	We	PRP	B-NP
O	435	447	hypothesized	hypothesize	VBD	B-VP
O	448	452	that	that	IN	B-SBAR
O	453	455	an	an	DT	B-NP
O	456	466	additional	additional	JJ	I-NP
O	467	473	direct	direct	JJ	I-NP
O	474	485	consequence	consequence	NN	I-NP
O	486	488	of	of	IN	B-PP
O	489	491	FH	FH	NN	B-NP
O	492	502	deficiency	deficiency	NN	I-NP
O	503	505	is	be	VBZ	B-VP
O	506	509	the	the	DT	B-NP
O	510	523	establishment	establishment	NN	I-NP
O	524	526	of	of	IN	B-PP
O	527	528	a	a	DT	B-NP
O	529	541	biosynthetic	biosynthetic	JJ	I-NP
O	542	548	milieu	milieu	NN	I-NP
O	548	549	.	.	.	O

O	550	552	To	To	TO	B-VP
O	553	564	investigate	investigate	VB	I-VP
O	565	569	this	this	DT	B-NP
O	570	580	hypothesis	hypothesis	NN	I-NP
O	580	581	,	,	,	O
O	582	584	we	we	PRP	B-NP
O	585	593	isolated	isolate	VBD	B-VP
O	594	601	primary	primary	JJ	B-NP
B-Cell	602	607	mouse	mouse	NN	I-NP
I-Cell	608	617	embryonic	embryonic	JJ	I-NP
I-Cell	618	628	fibroblast	fibroblast	NN	I-NP
I-Cell	629	630	(	(	(	O
I-Cell	630	633	MEF	MEF	NN	B-NP
I-Cell	633	634	)	)	)	O
I-Cell	635	640	lines	line	NNS	B-NP
O	641	645	from	from	IN	B-PP
O	646	649	Fh1	Fh1	NN	B-NP
O	649	650	-	-	HYPH	B-NP
O	650	659	deficient	deficient	JJ	I-NP
O	660	664	mice	mouse	NNS	I-NP
O	664	665	.	.	.	O

O	666	668	As	As	IN	B-SBAR
O	669	678	predicted	predict	VBN	B-VP
O	678	679	,	,	,	O
O	680	685	these	these	DT	B-NP
B-Cell	686	690	MEFs	MEF	NNS	I-NP
O	691	702	upregulated	upregulate	VBD	B-VP
O	703	706	Hif	Hif	NN	B-NP
O	706	707	-	-	HYPH	B-NP
O	707	713	1alpha	1alpha	NN	I-NP
O	714	717	and	and	CC	I-NP
O	718	721	HIF	HIF	NN	I-NP
O	722	728	target	target	NN	I-NP
O	729	734	genes	gene	NNS	I-NP
O	735	743	directly	directly	RB	B-ADVP
O	744	746	as	as	IN	B-PP
O	747	748	a	a	DT	B-NP
O	749	755	result	result	NN	I-NP
O	756	758	of	of	IN	B-PP
O	759	761	FH	FH	NN	B-NP
O	762	772	deficiency	deficiency	NN	I-NP
O	772	773	.	.	.	O

O	774	776	In	In	IN	B-PP
O	777	785	addition	addition	NN	B-NP
O	785	786	,	,	,	O
O	787	795	detailed	detail	VBD	B-VP
O	796	805	metabolic	metabolic	JJ	B-NP
O	806	816	assessment	assessment	NN	I-NP
O	817	819	of	of	IN	B-PP
O	820	825	these	these	DT	B-NP
B-Cell	826	830	MEFs	MEF	NNS	I-NP
O	831	840	confirmed	confirm	VBD	B-VP
O	841	846	their	their	PRP$	B-NP
O	847	857	dependence	dependence	NN	I-NP
O	858	860	on	on	IN	B-PP
O	861	871	glycolysis	glycolysis	NN	B-NP
O	871	872	,	,	,	O
O	873	876	and	and	CC	O
O	877	879	an	an	DT	B-NP
O	880	888	elevated	elevate	VBN	I-NP
O	889	893	rate	rate	NN	I-NP
O	894	896	of	of	IN	B-PP
O	897	904	lactate	lactate	NN	B-NP
O	905	911	efflux	efflux	NN	I-NP
O	911	912	,	,	,	O
O	913	923	associated	associate	VBN	B-VP
O	924	928	with	with	IN	B-PP
O	929	932	the	the	DT	B-NP
O	933	945	upregulation	upregulation	NN	I-NP
O	946	948	of	of	IN	B-PP
O	949	959	glycolytic	glycolytic	JJ	B-NP
O	960	967	enzymes	enzyme	NNS	I-NP
O	968	973	known	know	VBN	B-VP
O	974	976	to	to	TO	I-VP
O	977	979	be	be	VB	I-VP
O	980	990	associated	associate	VBN	I-VP
O	991	995	with	with	IN	B-PP
O	996	1009	tumorigenesis	tumorigenesis	NN	B-NP
O	1009	1010	.	.	.	O

O	1011	1026	Correspondingly	Correspondingly	RB	B-ADVP
O	1026	1027	,	,	,	O
B-Pathological_formation	1028	1031	Fh1	Fh1	NN	B-NP
I-Pathological_formation	1031	1032	-	-	HYPH	B-NP
I-Pathological_formation	1032	1041	deficient	deficient	JJ	I-NP
I-Pathological_formation	1042	1048	benign	benign	JJ	I-NP
I-Pathological_formation	1049	1055	murine	murine	JJ	I-NP
I-Pathological_formation	1056	1061	renal	renal	JJ	I-NP
I-Pathological_formation	1062	1067	cysts	cyst	NNS	I-NP
O	1068	1071	and	and	CC	O
O	1072	1074	an	an	DT	B-NP
O	1075	1083	advanced	advance	VBN	I-NP
O	1084	1089	human	human	JJ	I-NP
B-Cancer	1090	1095	HLRCC	HLRCC	NN	I-NP
I-Cancer	1095	1096	-	-	HYPH	O
I-Cancer	1096	1103	related	relate	VBN	B-NP
I-Cancer	1104	1109	renal	renal	JJ	I-NP
I-Cancer	1110	1114	cell	cell	NN	I-NP
I-Cancer	1115	1124	carcinoma	carcinoma	NN	I-NP
O	1125	1135	manifested	manifest	VBD	B-VP
O	1136	1137	a	a	DT	B-NP
O	1138	1147	prominent	prominent	JJ	I-NP
O	1148	1151	and	and	CC	I-NP
O	1152	1163	progressive	progressive	JJ	I-NP
O	1164	1172	increase	increase	NN	I-NP
O	1173	1175	in	in	IN	B-PP
O	1176	1179	the	the	DT	B-NP
O	1180	1190	expression	expression	NN	I-NP
O	1191	1193	of	of	IN	B-PP
O	1194	1197	HIF	HIF	NN	B-NP
O	1197	1198	-	-	HYPH	O
O	1198	1203	alpha	alpha	SYM	B-NP
O	1204	1210	target	target	NN	I-NP
O	1211	1216	genes	gene	NNS	I-NP
O	1217	1220	and	and	CC	B-PP
O	1221	1223	in	in	IN	B-PP
O	1224	1229	genes	gene	NNS	B-NP
O	1230	1235	known	know	VBN	B-VP
O	1236	1238	to	to	TO	I-VP
O	1239	1241	be	be	VB	I-VP
O	1242	1250	relevant	relevant	JJ	B-ADJP
O	1251	1253	to	to	TO	B-PP
O	1254	1267	tumorigenesis	tumorigenesis	NN	B-NP
O	1268	1271	and	and	CC	I-NP
O	1272	1282	metastasis	metastasis	NN	I-NP
O	1282	1283	.	.	.	O

O	1284	1286	In	In	IN	B-PP
O	1287	1293	accord	accord	NN	B-NP
O	1294	1298	with	with	IN	B-PP
O	1299	1302	our	our	PRP$	B-NP
O	1303	1313	hypothesis	hypothesis	NN	I-NP
O	1313	1314	,	,	,	O
O	1315	1317	in	in	IN	B-PP
O	1318	1319	a	a	DT	B-NP
O	1320	1327	variety	variety	NN	I-NP
O	1328	1330	of	of	IN	B-PP
O	1331	1340	different	different	JJ	B-NP
B-Tissue	1341	1343	FH	FH	NN	I-NP
I-Tissue	1343	1344	-	-	HYPH	B-NP
I-Tissue	1344	1353	deficient	deficient	JJ	I-NP
I-Tissue	1354	1361	tissues	tissue	NNS	I-NP
O	1361	1362	,	,	,	O
O	1363	1372	including	include	VBG	B-PP
O	1373	1374	a	a	DT	B-NP
O	1375	1380	novel	novel	JJ	I-NP
O	1381	1387	murine	murine	JJ	I-NP
O	1388	1393	model	model	NN	I-NP
O	1394	1396	of	of	IN	B-PP
B-Tissue	1397	1400	Fh1	Fh1	NN	B-NP
I-Tissue	1400	1401	-	-	HYPH	B-NP
I-Tissue	1401	1410	deficient	deficient	JJ	I-NP
I-Tissue	1411	1417	smooth	smooth	JJ	I-NP
I-Tissue	1418	1424	muscle	muscle	NN	I-NP
O	1424	1425	,	,	,	O
O	1426	1428	we	we	PRP	B-NP
O	1429	1433	show	show	VBP	B-VP
O	1434	1435	a	a	DT	B-NP
O	1436	1444	striking	striking	JJ	I-NP
O	1445	1448	and	and	CC	I-NP
O	1449	1460	progressive	progressive	JJ	I-NP
O	1461	1473	upregulation	upregulation	NN	I-NP
O	1474	1476	of	of	IN	B-PP
O	1477	1478	a	a	DT	B-NP
O	1479	1490	tumorigenic	tumorigenic	JJ	I-NP
O	1491	1500	metabolic	metabolic	JJ	I-NP
O	1501	1508	profile	profile	NN	I-NP
O	1508	1509	,	,	,	O
O	1510	1512	as	as	IN	B-SBAR
O	1513	1523	manifested	manifest	VBN	B-VP
O	1524	1526	by	by	IN	B-PP
O	1527	1536	increased	increase	VBN	B-NP
O	1537	1541	PKM2	PKM2	NN	I-NP
O	1542	1545	and	and	CC	I-NP
O	1546	1550	LDHA	LDHA	NN	I-NP
O	1551	1558	protein	protein	NN	I-NP
O	1558	1559	.	.	.	O

O	1560	1565	Based	Base	VBN	B-PP
O	1566	1568	on	on	IN	B-PP
O	1569	1572	the	the	DT	B-NP
O	1573	1579	models	model	NNS	I-NP
O	1580	1588	assessed	assess	VBN	B-VP
O	1589	1595	herein	herein	RB	B-ADVP
O	1595	1596	,	,	,	O
O	1597	1599	we	we	PRP	B-NP
O	1600	1605	infer	infer	VBP	B-VP
O	1606	1610	that	that	IN	B-SBAR
O	1611	1615	that	that	DT	B-NP
O	1616	1618	FH	FH	NN	B-NP
O	1619	1629	deficiency	deficiency	NN	I-NP
O	1630	1637	compels	compel	VBZ	B-VP
B-Cell	1638	1643	cells	cell	NNS	B-NP
O	1644	1646	to	to	TO	B-VP
O	1647	1652	adopt	adopt	VB	I-VP
O	1653	1655	an	an	DT	B-NP
O	1656	1661	early	early	JJ	I-NP
O	1661	1662	,	,	,	I-NP
O	1663	1673	reversible	reversible	JJ	I-NP
O	1673	1674	,	,	,	O
O	1675	1678	and	and	CC	O
O	1679	1690	progressive	progressive	JJ	B-NP
O	1691	1705	protumorigenic	protumorigenic	JJ	I-NP
O	1706	1715	metabolic	metabolic	JJ	I-NP
O	1716	1722	milieu	milieu	NN	I-NP
O	1723	1727	that	that	WDT	B-NP
O	1728	1730	is	be	VBZ	B-VP
O	1731	1742	reminiscent	reminiscent	JJ	B-ADJP
O	1743	1745	of	of	IN	B-PP
O	1746	1750	that	that	DT	B-NP
O	1751	1758	driving	drive	VBG	B-VP
O	1759	1762	the	the	DT	B-NP
O	1763	1770	Warburg	Warburg	NNP	I-NP
O	1771	1777	effect	effect	NN	I-NP
O	1777	1778	.	.	.	O

O	1779	1786	Targets	Target	NNS	B-NP
O	1787	1797	identified	identify	VBN	B-VP
O	1798	1800	in	in	IN	B-PP
O	1801	1806	these	these	DT	B-NP
O	1807	1812	novel	novel	JJ	I-NP
O	1813	1816	and	and	CC	I-NP
O	1817	1824	diverse	diverse	JJ	I-NP
O	1825	1827	FH	FH	NN	I-NP
O	1827	1828	-	-	HYPH	I-NP
O	1828	1837	deficient	deficient	JJ	I-NP
O	1838	1844	models	model	NNS	I-NP
O	1845	1854	represent	represent	VBP	B-VP
O	1855	1864	excellent	excellent	JJ	B-NP
O	1865	1874	potential	potential	JJ	I-NP
O	1875	1885	candidates	candidate	NNS	I-NP
O	1886	1889	for	for	IN	B-PP
O	1890	1897	further	further	JJ	B-NP
O	1898	1909	mechanistic	mechanistic	JJ	I-NP
O	1910	1923	investigation	investigation	NN	I-NP
O	1924	1927	and	and	CC	O
O	1928	1939	therapeutic	therapeutic	JJ	B-NP
O	1940	1949	metabolic	metabolic	JJ	I-NP
O	1950	1962	manipulation	manipulation	NN	I-NP
O	1963	1965	in	in	IN	B-PP
B-Cancer	1966	1972	tumors	tumor	NNS	B-NP
O	1972	1973	.	.	.	O

